Related Experiment Video

Updated: May 28, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Where now for anti-EGF receptor therapies in colorectal cancer?

Paul H S Shaw1, Richard A Adams

  • 1Department of Pathophysiology and Repair, School of Bioscience, Cardiff, University, Museum Avenue, Cardiff, CF10 3AX, UK. paul.shaw@wales.nhs.uk

Expert Review of Anticancer Therapy
|October 18, 2011
PubMed

Insights

Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) show promise for advanced colorectal cancer. This review covers their efficacy, resistance mechanisms, and predictive biomarkers for targeted therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) are US FDA-approved for advanced colorectal cancer.
  • Cetuximab and panitumumab are key examples of these targeted therapies.

Purpose of the Study:

  • To review clinical evidence for anti-EGFR monoclonal antibodies in advanced colorectal cancer.
  • To discuss predictive molecular biomarkers associated with anti-EGFR therapy.
  • To explore resistance mechanisms and potential counter-strategies for anti-EGFR therapy.

Main Methods:

  • Literature review of clinical evidence.
  • Analysis of molecular biomarker data.
  • Discussion of resistance evolution and therapeutic strategies.

Main Results:

  • Anti-EGFR antibodies demonstrate clinical utility in advanced colorectal cancer.
  • Predictive molecular biomarkers are emerging for patient stratification.
  • Understanding resistance mechanisms is crucial for sustained efficacy.

Conclusions:

  • Targeted anti-EGFR therapy offers a valuable approach for advanced colorectal cancer.
  • Biomarker-driven treatment and strategies to overcome resistance are essential.
  • Further research into resistance mechanisms will refine therapeutic approaches.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.